Aquyn Varmasiotics said on Sunday that an experimental drug for the treatment of Alzheimer’s developed by the company passed a provisional safety test and moved to greater experiences. This drug is aimed at a new form of the toxic protein component “beta amyloid” in the brain. The company said the AI 193 property was well received in the first patient test experience. The company presented the results of the study, conducted on a random sample, including 62 patients with early symptoms of Alzheimer’s at the International Conference of the Alzheimer’s Association in Amsterdam. The study included a comparison between a group of participants who found the property with another group that got a false property. Dr. Akymen’s chief medical official, Eric Simmers, said that the new drug developed by the company targeted and linked to some units of the beta amyloid, which is a toxic version soluble from the amyloid protein, which is a brain plate associated with the disease. According to the Aquil’s experience, the company said that those who get larger doses of the new property will lower the rate of amyloid paintings to a period of between 6 weeks and 12 weeks, indicating that the drug can be given to patients once a month. Also read:
A new remedy for Alzheimer’s treatment passes a preliminary safety test
